🟠 Moderate Evidence
Weight loss achieved through calorie restriction typically involves loss of both fat and lean mass in predictable proportions. Research shows that approximately 25% of weight lost during dietary interventions comes from lean mass rather than fat — a pattern termed the “Quarter Rule” in body composition research. However, data from semaglutide clinical trials suggest that this glucagon-like peptide-1 receptor agonist may accelerate lean mass loss beyond what diet alone would produce, though emerging evidence indicates this effect may be modifiable with targeted interventions.
Key takeaways
- The “Quarter Rule” establishes that roughly 25% of weight lost through calorie restriction comes from lean mass; this holds across meta-analyses of dietary studies and bariatric surgery (~20–24%)
- Tirzepatide and liraglutide align with expected lean mass loss ratios (26% and 16%, respectively), but semaglutide exceeds the benchmark, with 35–40% of weight loss attributed to lean mass in dual-energy X-ray absorptiometry substudies
- Preliminary case data suggest that resistance training combined with adequate protein intake (0.7–1.7 g/kg/day) may preserve or even increase lean mass during incretin therapy, despite substantial overall weight loss
Study at a Glance
| Evidence source | SURMOUNT-1, STEP 1, and COURAGE clinical trials |
| Study design | Randomised controlled trials with dual-energy X-ray absorptiometry substudies |
| Duration | 68–72 weeks for primary weight loss measurement |
| Intervention | Semaglutide, tirzepatide, liraglutide, and diet-only control |
| Primary outcome | Percentage of total weight loss attributable to lean mass |
Lean mass as percentage of total weight loss across interventions
Data from clinical trials and meta-analyses; higher values indicate greater lean mass loss relative to total weight reduction
Source: STEP 1 (semaglutide), SURMOUNT-1 (tirzepatide), COURAGE trial (semaglutide), dietary meta-analyses | Georgian Medical Journal News
Semaglutide diverges from the lean mass norm
When the STEP 1 trial measured body composition using dual-energy X-ray absorptiometry (DXA) over 68 weeks, semaglutide produced 21.3% total body weight loss — a figure consistent with other incretin therapies. However, the composition of that loss diverged sharply from expectation: 40% of the weight lost was lean mass, compared to the 25% benchmark established across dietary intervention meta-analyses. The COURAGE trial reported a somewhat lower figure of approximately 35%, suggesting that 40% may represent an upper bound rather than a consistent effect. Nevertheless, even the lower estimate substantially exceeds the diet-only baseline.
By contrast, tirzepatide in the SURMOUNT-1 trial demonstrated 21.3% total weight loss with 26% attributable to lean mass — a ratio that falls squarely within expected ranges. Liraglutide, measured in a smaller 6-month cohort, resulted in 16% lean mass loss, also consistent with dietary norms. This suggests that the elevated lean mass loss observed with semaglutide may reflect a distinct physiological mechanism not shared equally across the GLP-1 receptor agonist class.
Measurement caveats and what DXA actually quantifies
An important technical distinction complicates interpretation of these findings. DXA-measured “lean body mass” encompasses not only skeletal muscle but also water, organ tissue, and connective tissue. During weight reduction, some proportion of measured lean mass loss reflects adaptive remodeling of these tissues — fluid shifts, metabolic adjustment, and tissue turnover — rather than direct skeletal muscle catabolism. A portion of the excess lean mass loss observed with semaglutide may therefore represent physiological adaptation rather than pathological muscle wasting. This distinction has practical implications: tissue water and metabolic organ remodeling can be partially recovered, whereas true muscle loss requires deliberate rebuilding. See Clinical Updates for ongoing guidance on body composition assessment.
Notably, none of the major GLP-1 or GLP-1/GIP trials — including STEP 1, SURMOUNT-1, and COURAGE — mandated resistance training or set specific protein targets during weight loss. All included lifestyle counseling, but the degree of emphasis on muscle-preserving strategies varied. This represents a potential opportunity: if lean mass loss is driven partly by inadequate resistance stimulus or suboptimal protein intake, targeted intervention might mitigate the effect.
Resistance training and protein offset lean mass loss
Emerging preliminary evidence supports this possibility. A recent case series described patients who combined incretin therapy with structured resistance training (3–5 sessions per week) and protein intakes ranging from 0.7 to 1.7 g/kg/day. One patient who lost 33% of total body weight achieved a lean mass loss of only 6.9% — substantially below the 40% observed in STEP 1. Two additional patients with higher protein intakes (toward the upper end of the range) actually gained lean mass while losing 13–27% of body weight, a finding that contradicts the assumed inevitability of lean loss during weight reduction with semaglutide.
These results remain preliminary and require confirmation in larger, controlled cohorts. However, they suggest that the elevated lean mass loss associated with semaglutide may be modifiable through behavioural intervention. If replicated, this would shift the clinical conversation: rather than accepting elevated lean loss as an immutable side effect, clinicians might counsel patients receiving semaglutide to implement structured exercise and ensure adequate protein intake — interventions known to preserve muscle in other weight loss contexts.
Semaglutide produced 40% lean mass loss in the STEP 1 dual-energy X-ray absorptiometry substudy, compared to 25% in diet-only weight loss, but preliminary case data suggest that resistance training combined with adequate protein intake (0.7–1.7 g/kg/day) may reduce or reverse this effect.
— Evidence from STEP 1 trial (68 weeks), COURAGE trial, and preliminary case series
What this means
Frequently asked questions
Why does semaglutide cause more lean mass loss than tirzepatide or liraglutide?
The mechanism is not yet fully characterised. Semaglutide achieves greater appetite suppression and weight loss velocity than other incretin therapies at equivalent doses, which may intensify adaptive lean tissue loss. Differences in receptor subtype activation or metabolic effects on muscle protein synthesis remain under investigation. New Studies sections track emerging mechanistic data as it becomes available.
Is lean mass loss from semaglutide reversible?
Partially. Water and organ tissue remodelling (measured but not true muscle) can normalise with weight stabilisation. True skeletal muscle loss is reversible only through resistance training and adequate protein intake. The case series evidence suggests that if lean loss is prevented during weight reduction through exercise and protein adequacy, recovery becomes unnecessary — muscle is preserved rather than lost and rebuilt.
Should everyone on semaglutide do resistance training?
Current evidence supports it as standard recommendation rather than optional add-on. While large randomised controlled trials testing resistance training plus semaglutide are lacking, the rationale is sound: resistance training mitigates lean loss in other weight loss contexts, and preliminary semaglutide data are encouraging. Individualisation based on age, comorbidity, and exercise tolerance remains essential.
As incretin therapies become increasingly prescribed for weight management, the clinical focus is shifting from weight loss alone to body composition quality — preserving muscle while reducing fat. The evidence that semaglutide accelerates lean loss beyond dietary norms is now clear. What remains to be established at scale is whether structured exercise and protein targets can routinely offset this effect. Future trials that mandate resistance training and protein adequacy as protocol components, with DXA measurement as a primary outcome, will provide definitive guidance. In the interim, clinicians have sufficient preliminary evidence to recommend these interventions and reasonable grounds to expect improved body composition outcomes.
Source: STEP 1 Trial: Body Composition Outcomes in Semaglutide-Treated Obesity, SURMOUNT-1 Trial: Tirzepatide Body Composition Analysis, Meta-analyses of Dietary Intervention Lean Mass Loss
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
